According to "The Big Banks," Bank of America Securities has lowered the target price for WUXI BIO to 39.5 yuan with a rating of "Neutral."

Bank of America Securities published a research report stating that WUXI BIO (02269.HK) had a revenue increase of 16.7% year-on-year to RMB 21.8 billion last year, in line with expectations. The gross profit reached RMB 10 billion, with a gross margin increase of 5 percentage points to 46%, benefiting from a higher contribution from royalties or milestone revenues and improved capacity utilization. The net profit attributable to shareholders was RMB 4.9 billion, an increase of 46.3% compared to the same period last year.

The bank indicated that it has lowered its revenue forecasts for 2026 to 2028 by 4% to 8%, and reduced the gross margin by 0.4 percentage points. The target price has been lowered from RMB 47 to RMB 39.5, with a rating of "Neutral."